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Scarlet fever outbreak in Hong Kong, 2011Yu-Chia Hsieh a,b, Yhu-Chering Huang a,b,*aDivision of Pediatric Infectious Diseases, Department of Pediatrics, Chang Gung Children’s Hospital,
Chang Gung Memorial Hospital, Taoyuan County, Taiwan
bCollege of Medicine, Chang Gung University, Taoyuan County, TaiwanAn outbreak of scarlet fever hit Hong Kong in 2011. At least
600 cases of scarlet fever have been reported in Hong Kong
till the end of June 2011, with two resulting in deaths. The
first fatal case, a 7-year-old girl, presented with fever, sore
throat, vomiting, and skin rash on May 20. She consulted
a private doctor first but her condition did not improve. She
was referred and admitted to Queen Mary’s Hospital on May
27. Her condition further deteriorated and complicated
with toxic shock syndrome. She passed away on May 29. The
second fatal case, a 5-year-old boy, presented with fever
from June 15. He was admitted to Princess Margaret
Hospital on June 19 for sudden deterioration in condition.
The boy developed toxic shock syndrome and passed away
on June 21. He had consulted a general practitioner for
chickenpox earlier. Further laboratory investigation showed
that the isolates of Streptococcus pyogenes from both fatal
cases belonged to different strains. Emm12 and emm1 were
identified for both S pyogenes isolates. University of Hong
Kong scientists said that they had discovered a mutation of
the main isolates, making it more contagious and deadly.
The new strain was more resistant to erythromycin and
clindamycin, a resistance rate increasing from 10e30%
previously to 60%, by picking up one or more genes from
bacteria normally found in the human oral and urogenital
tracts. Because Hong Kong and Taiwan are very close, both
geographical location and people, it is quite common for
people living in Taiwan to travel to Hong Kong, and thus,* Corresponding author. Division of Pediatric Infectious Diseases,
Department of Pediatrics, Chang Gung Children’s Hospital, Chang
Gung Memorial Hospital, No. 5, Fu-Hsin Street, Kwei-Shan Hsiang,
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doi:10.1016/j.jmii.2011.07.003the possibility of the mutated strain being imported
into Taiwan is high. Both the health authorities and
professionals should be alert on this disease and meticu-
lously monitor the progression of this epidemic.
Group A streptococcus (GAS) (S pyogenes) is among the
most common and versatile of human pathogens. It causes
human diseases ranging from noninvasive infections, such as
pharyngitis, impetigo, cellulitis, and scarlet fever, to life-
threatening conditions, such as bacteremia, necrotizing
fasciitis, and streptococcal toxic shock syndrome (STSS).
The M protein encoded by the emm gene is a major virulence
factor of GAS. M1, M2, M3, M4, M6, and M22 strains have
been shown to be associated with outbreaks of scarlet
fever.1e4 M1 and M3 were associated with invasive disease
and fatal infections in Britain from 1980 to 1990 and in the
United States from 1995 to 1999,5,6 and M18 was associated
with acute rheumatic fever.7 Nowadays, epidemiological
studies usually use sequence analysis of the 50 end of the
emm gene to define GAS strains.
Scarlet fever is one of the most common infections
caused by GAS in school children. Clinical features of
scarlet fever include a sore throat, skin rash, and straw-
berry tongue. In Taiwan, scarlet fever was listed as
a national notifiable disease till 2007. The number of cases
of scarlet fever in Taiwan fluctuated yearly and had
geographic variations in different parts of Taiwan. Yan
et al3 analyzed 77 GAS isolates collected from patients with
scarlet fever between 1993 and 2002 in southern Taiwan
and found only three emm types among the isolates, with
emm1 being the most prevalent type. Later, Su et al8
reported that emm12, emerging in 2005 and peaking in
2007, was the major emm type associated with scarlet
fever between 1998 and 2007 in southern Taiwan. In
northern Taiwan, Chen et al9 characterized 830 isolatesished by Elsevier Taiwan LLC. All rights reserved.
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between 2001 and 2002, and found that emm1 (29.2%),
emm4 (24.1%), emm12 (19.0%), emm6 (15.8%), stIL103
(5.7%), and emm22 (1.9%) were the most frequent emm
types. In central Taiwan, emm12, emm4, emm1, emm6,
and emm22 were the five most common emm types among
GAS isolates causing scarlet fever.10,11 The geographic
variation in the prevalence of emm clones accounted for
the difference in the epidemiological trend of scarlet fever
in different parts of Taiwan in different years.
Most deaths caused by GAS were because of invasive
diseases. Since late 1980s, there has been a marked
increase of STSS, which was associated with shock and
multiple-organ failure.12e15 A new, highly virulent subclone
of serotype M1T1, being studied to evolve as a result of
diversification of the bacteria and acquisition of new genes,
emerged to cause severe diseases.16 In Taiwan, Huang
et al17 reported a family cluster of STSS in children. Among
adults in Taiwan, M1 serotype was significantly associated
with the clinical signs of STSS and with mortality.18
Recently, Chiang-Ni et al19 showed that the emergence of
uncommon emm type of GAS, including emm13, emm81,
and emm106, was noted in patients older than 50 years and
was significantly associated with a specific invasive disease
manifestation in southern Taiwan. Close epidemiological
and microbiological surveillance of GAS disease is war-
ranted. Currently, there is no definitive treatment against
the toxins. Treatment for STSS includes supportive hemo-
dynamic stabilization, surgical debridement if site of
infection is identified, and antibiotic therapy.20 In addition
to penicillin, clindamycin can be used to improve survival
by inhibiting protein synthesis. The Centers for disease
control of United States does not recommend the routine
administration of chemoprophylaxis to all household
contacts of the person with invasive GAS disease. Health
care providers routinely inform household contacts of the
person with invasive GAS disease about the clinical mani-
festations of pharyngeal injection and invasive GAS disease,
and to seek immediate medical attention if they develop
such symptoms.21
GAS isolates in Taiwan were susceptible to penicillin,
cefotaxime, cefepime, meropenem (Sumitomo Pharmaceu-
ticals, Tokyo, Japan), moxifloxacin (Bayer Co., Leverkusen,
Germany), vancomycin (Eli Lilly & Co., Indianapolis, IN,
USA), linezolid (Pharmacia, Kalamazoo, MI, USA).22 Before
2000, the rate of macrolide resistance in GAS reached
40e60%.23 Under a restrictive governmental policy, which
has been implemented in 2001, the rate of macrolide resis-
tance to GAS decreased to 17%.23 A 26-valent recombinant M
protein vaccine (including Types 1, 1.2, 2, 3, 5, 6, 11, 12, 14,
18, 19, 22, 24, 28, 29, 33, 43, 59, 75, 76, 77, 89, 92, 94, 101,
and 104) is under clinical trials and was found to be safe and
immunogenic in adults.24 On the basis of epidemiological
data, the current formulation of the experimental multiva-
lent vaccine would provide good coverage in high-income
countries where GAS diseases were caused by a limited
number of seroytpes, but poor coverage in Africa and the
Pacific area, and only average coverage in Asia and the
Middle East. More trials are needed to prove that the
multivalent vaccine is effective and could be potentially
administrated to pre-school-aged children to prevent GAS
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